Welcome to our dedicated page for Regenxbio SEC filings (Ticker: RGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The REGENXBIO Inc. (RGNX) SEC filings page brings together the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biotechnology issuer focused on AAV gene therapy, REGENXBIO uses current reports on Form 8-K and other filings to communicate material information about its operations, clinical programs, collaborations and financial condition.
Recent 8-K filings illustrate how the company reports key developments. One Form 8-K describes the issuance of a press release covering financial results and operational highlights for the quarter ended September 30, 2025, including updates on late-stage programs such as RGX-202 for Duchenne muscular dystrophy, clemidsogene lanparvovec (RGX-121) for MPS II and surabgene lomparvovec (ABBV-RGX-314, sura-vec) for retinal disease. Another 8-K details the FDA’s extension of the Prescription Drug User Fee Act (PDUFA) action date for the RGX-121 Biologics License Application for MPS II, moving the date to February 8, 2026 to allow review of additional data.
REGENXBIO also uses Form 8-K to disclose significant collaboration changes. An 8-K filed in August 2025 outlines a first amendment to the collaboration and license agreement with AbbVie, which modifies the development plan and milestone structure for the diabetic retinopathy program using suprachoroidal delivery and adds further AbbVie-led investment in the subretinal wet AMD program. The filing explains new milestone payment terms tied to first patient dosing in registration-enabling trials and references a joint press release attached as an exhibit.
On this page, investors can review such 8-Ks alongside other SEC documents to understand how REGENXBIO reports clinical milestones, regulatory interactions, collaboration amendments and financial results. Stock Titan’s tools can help surface the most recent filings, while AI-powered summaries can clarify the main points of lengthy documents, highlight items such as PDUFA date changes or collaboration amendments, and make it easier to follow how these disclosures relate to the company’s gene therapy pipeline and RGNX stock.
REGENXBIO Inc.'s Chief Strategy & Legal Officer, Patrick J. Christmas, reported new equity awards. On January 6, 2026, he received 73,749 shares of common stock through a time-based restricted stock unit award at a price of $0.00 per share. According to the award terms, 25% of these RSUs will vest on each of January 6, 2027, 2028, 2029 and 2030, as long as he continues providing service to the company.
He was also granted stock options for 39,650 shares of common stock with an exercise price of $14.18 per share. These options vest 25% after 12 months of continuous service, with the remaining balance vesting in equal monthly installments over the 36 months following January 6, 2027, subject to continued service, and expire on January 6, 2036. After these transactions, he directly holds 215,367 shares of common stock and 39,650 stock options.
REGENXBIO Inc. reported that its Chief Financial Officer, Mitchell Chan, received new equity awards on January 6, 2026. He was granted 73,749 shares of common stock underlying a time-based restricted stock unit (RSU) award at a grant price of $0.00 per share. These RSUs vest in four equal installments of 25% each on January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030, as long as he continues providing service to the company.
Chan also received 39,650 stock options with an exercise price of $14.18 per share, expiring on January 6, 2036. For this option grant, 25% of the shares vest after 12 months of continuous service, with the remaining 75% vesting in equal monthly installments over the 36 months following January 6, 2027. After these reported grants, he directly beneficially owned 127,717 shares of common stock and 39,650 stock options.
REGENXBIO Inc. Chief Strategy & Legal Officer Patrick J. Christmas reported a tax-related share withholding transaction. On January 2, 2026, 9,793 shares of REGENXBIO common stock were withheld at a price of $14.4 per share to cover taxes due upon the vesting of previously granted restricted stock units.
These restricted stock units were originally granted on January 3, 2022, January 3, 2023 and January 2, 2024. After this withholding, Christmas beneficially owned 141,618 shares of REGENXBIO common stock, held directly.
REGENXBIO Inc. filed a shelf registration statement allowing it to offer and sell up to $300,000,000 of securities over time. The mix may include common stock, preferred stock, warrants, debt securities, rights and units, in one or more offerings, with final terms set in future prospectus supplements. Any securities can be sold directly, or through underwriters, dealers or agents.
REGENXBIO, a gene therapy-focused biotechnology company, plans to use net proceeds for general corporate purposes, including financing clinical trials, capital expenditures, working capital, pipeline development, expanding commercial capabilities, general and administrative expenses, potential debt repayment and possible acquisitions or investments. Its common stock trades on the Nasdaq Global Select Market under the symbol RGNX and closed at $13.45 on November 25, 2025. As of September 30, 2025, 50,618,692 shares of common stock were outstanding.
REGENXBIO Inc. (RGNX) furnished quarterly results. The company submitted an 8‑K announcing it issued a press release covering results of operations and financial condition for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and incorporated by reference therein.
The information under Item 2.02 and Exhibit 99.1 is furnished, not filed, under the Exchange Act. REGENXBIO’s common stock trades on the Nasdaq Global Select Market under the symbol RGNX.
REGENXBIO Inc. reported Q3 2025 results. Total revenue was $29.7 million, driven by $23.6 million of license and royalty revenue and $6.1 million of service revenue. For the nine months, revenue reached $140.1 million.
The company posted a Q3 net loss of $61.9 million and a basic and diluted net loss per share of $1.20. Interest expense rose to $13.2 million in the quarter, reflecting royalty financing activity. Operating expenses were $82.1 million in Q3, led by $56.1 million in research and development and $20.3 million in general and administrative costs.
Cash, cash equivalents and marketable securities totaled $302.0 million as of September 30, 2025. Royalty monetization liabilities increased to $191.6 million, including a new 2025 Royalty Bond initially funded with $150.0 million (net proceeds $144.5 million). Deferred revenue rose to $34.4 million current and non-current combined, aligned with recent collaboration activity and the new presentation separating service revenue. Shares outstanding were 50,623,086 as of October 31, 2025.
Simpson Curran, who is listed as both Chief Executive Officer and a Director of REGENXBIO Inc. (RGNX), reported an open-market sale of company common stock under a pre-existing trading plan. On
Following this reported transaction the reporting person beneficially owned 216,162 shares. The Form 4 was signed via attorney-in-fact on
REGENXBIO, Inc. (RGNX) filed a Form 144 notifying the proposed sale of 20,811 common shares with an aggregate market value of
The filing discloses recent Rule 10b5-1 sales by the same person: 7,624 shares sold on
Simpson Curran, serving as Chief Executive Officer and a director of REGENXBIO Inc. (RGNX), reported a sale of 7,624 shares of the issuer's common stock on 09/29/2025. The sale was effected under a Rule 10b5-1 trading plan and executed in multiple trades at prices ranging from $10.00 to $10.08, with a weighted average sale price of $10.03. Following the reported transaction, the reporting person beneficially owned 236,973 shares, held directly. The Form 4 was signed by an attorney-in-fact, Patrick J. Christmas, on 10/01/2025. No derivative transactions or other securities classes were reported in this filing.
REGENXBIO Inc. (RGNX) filed a Form 144 notifying the proposed sale of 15,358 shares of its common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $151,890.62 and an approximate planned sale date of 09/10/2025 on NASDAQ.
The shares were acquired as Restricted Stock Units from the issuer on 01/01/2023 and total outstanding shares are reported as 50,514,216, making the planned sale approximately 0.03% of outstanding stock. The filing affirms the signer does not possess undisclosed material adverse information and indicates no securities were sold in the past three months by the reporting person.